Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Shares Outstanding (Weighted Average) (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 408.93% to $10.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.1 million through Dec 2025, up 408.93% year-over-year, with the annual reading at $10.1 million for FY2025, 408.93% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $10.1 million in Q4 2025 for Mangoceuticals, up from $997899.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $15.8 million in Q2 2023 to a low of $997899.0 in Q3 2025.
  • Historically, Shares Outstanding (Weighted Average) has averaged $4.5 million across 3 years, with a median of $1.8 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 89.61% in 2024 and later soared 408.93% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $1.1 million in 2023, then skyrocketed by 84.23% to $2.0 million in 2024, then skyrocketed by 408.93% to $10.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for MGRX at $10.1 million in Q4 2025, $997899.0 in Q3 2025, and $1.4 million in Q2 2025.